Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**RO5503781 + posaconazole** is an investigational combination of RO5503781, a small molecule cancer growth inhibitor, and posaconazole, a triazole antifungal agent. RO5503781 acts as a biological therapy and cancer growth blocker, disrupting signals necessary for cancer cells to divide and proliferate. Posaconazole inhibits 14-alpha demethylase in fungi, blocking ergosterol synthesis, and is used to treat and prevent invasive fungal infections, especially in immunocompromised patients. The combination has been studied in clinical trials, primarily to assess pharmacokinetics, safety, and drug-drug interaction in patients with solid tumors, with particular interest in mutual pharmacological influences and safety profile[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RO5503781 + posaconazole.